These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 14630265)

  • 41. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
    Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biochemical control and toxicity for favorable- and intermediate-risk patients using real-time intraoperative inverse optimization prostate seed implant: Less is more!
    Shukla G; Sarkar A; Hanlon A; Crockett E; Chen HC; Martelli-Raben J; Glick A; Benge B; Lobis M; Terranova S; Desperito T; Cozzolino D; Kemmerer E; Mourtada F; Raben A
    Brachytherapy; 2017; 16(3):490-496. PubMed ID: 28185762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial.
    Merrick GS; Wallner KE; Butler WM; Galbreath RW; Taira AV; Orio P; Adamovich E
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e449-55. PubMed ID: 22196131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term biochemical control and cause-specific survival in men with Gleason grade Group 4 and 5 prostate cancer treated with brachytherapy and external beam irradiation.
    Stone NN; Skouteris V; Stock RG
    Brachytherapy; 2020; 19(3):275-281. PubMed ID: 32217039
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
    Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
    Potters L; Huang D; Fearn P; Kattan MW
    Brachytherapy; 2003; 2(1):26-31. PubMed ID: 15062160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses.
    Lee LN; Barnswell C; Torre T; Fearn P; Kattan M; Potters L
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):282-9. PubMed ID: 12023131
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
    Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Fearn PA; Kattan MW; Stock RG
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1472-7. PubMed ID: 17689026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biochemical outcome for hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Urology; 2002 Jul; 60(1):98-103. PubMed ID: 12100932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Palladium-103 brachytherapy for prostate carcinoma.
    Blasko JC; Grimm PD; Sylvester JE; Badiozamani KR; Hoak D; Cavanagh W
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):839-50. PubMed ID: 10705004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose response in prostate cancer with 8-12 years' follow-up.
    Hanks GE; Hanlon AL; Epstein B; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.
    Zelefsky MJ; Hollister T; Raben A; Matthews S; Wallner KE
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1261-6. PubMed ID: 10889379
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate brachytherapy: treatment strategies.
    Stone NN; Stock RG
    J Urol; 1999 Aug; 162(2):421-6. PubMed ID: 10411050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy.
    Bostancic C; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath R; Lief J; Gutman SE
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1431-7. PubMed ID: 17544597
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization.
    Stock RG; Stone NN; Kao J; Iannuzzi C; Unger P
    Cancer; 2000 Oct; 89(8):1829-34. PubMed ID: 11042580
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials.
    Ghaly M; Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1288-93. PubMed ID: 12654439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.